LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

被引：17
|
作者：
Vanover, Kimberly [1 ]
Dmitrienko, Alex [2 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Saillard, Jelena [1 ]
Weingart, Michal [1 ]
Satlin, Andrew [1 ]
Mates, Sharon [1 ]
Correll, Christoph [3 ]
Davis, Robert [1 ]
机构：
[1] Intra Cellular Therapies Inc, New York, NY USA
[2] Mediana Res, Ljubljana, Slovenia
[3] Hofstra North Shore LIJ Sch Med, Zucker Hillside Hosp, Hempstead, NY USA
来源：
SCHIZOPHRENIA BULLETIN | 2018年 / 44卷
关键词：
D O I：
10.1093/schbul/sby018.831
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
S44
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [1] THE CLINICAL DEVELOPMENT OF LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA
    Vanover, Kimberly
    Correll, Christoph
    Dmitrienko, Alex
    Glass, Steve
    O'Gorman, Cedric
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    Davis, Robert
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S16 - S16
  • [2] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
    Correll, C. U.
    Vanover, K. E.
    Durgam, S.
    Weingart, M.
    Davis, R.
    Satlin, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456
  • [3] Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia
    Vanover, Kimberly
    Correll, Christoph
    Weingart, Michal
    Saillard, Jelena
    Hossain, Shawn
    Glass, Steven
    Kozauer, Susan
    Satlin, Andrew
    Davis, Robert
    [J]. NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S328 - S329
  • [4] Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial
    Suppes, Trisha
    Durgam, Suresh
    Kozauer, Susan G.
    Chen, Richard
    Lakkis, Hassan D.
    Davis, Robert E.
    Satlin, Andrew
    Vanover, Kimberly E.
    Mates, Sharon
    McIntyre, Roger S.
    Tohen, Mauricio
    [J]. BIPOLAR DISORDERS, 2023, 25 (06) : 478 - 488
  • [5] Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia
    Satlin, Andrew
    Vanover, Kimberly
    Durgam, Suresh
    Mates, Sharon
    Davis, Robert
    Correll, Christoph
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 493 - 494
  • [6] LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
    Davis, Robert
    Dmitrienko, Alex
    Glass, Steven
    Kozauer, Susan
    Saillard, Jelena
    Weingart, Michal
    Satlin, Andrew
    Mates, Sharon
    Correll, Christoph
    Vanover, Kimberly
    [J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S236 - S237
  • [7] Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study
    Satlin, A.
    Durgam, S.
    Vanover, K. E.
    Davis, R. E.
    Chen, R.
    Mates, S.
    Correll, C. U.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S265 - S266
  • [8] Metabolic syndrome in bipolar depression with lumateperone (iti-007): a post hoc analysis of 2 randomized, placebo-controlled trials
    Correll, Christoph
    Durgam, Suresh
    Kozauer, Susan G.
    Martin, Margaret
    Huo, Jason
    Mates, Sharon
    [J]. BIPOLAR DISORDERS, 2022, 24 : 54 - 54
  • [9] The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
    Longo, Giulio
    Cicolini, Angelica
    Orsolini, Laura
    Volpe, Umberto
    [J]. BRAIN SCIENCES, 2023, 13 (12)
  • [10] Metabolic Syndrome in Bipolar Depression with Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials
    Correll, Christoph U.
    Kozauer, Susan G.
    Lands, Micah
    Huo, Jason
    Durgam, Suresh
    [J]. CNS SPECTRUMS, 2023, 28 (02) : 247 - 248
12345